ArticleOncotarget2016
Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Cancer-driver-agnostic targeting of amplified surface proteins identifies MPZL1 for selective CAR-T cell therapy.Nature communications · 2026Article
- A novel 5-gene prognostic signature to improve risk stratification of cytogenetically normal acute myeloid leukemia.Journal of cancer research and clinical oncology · 2023Article
- High trophinin-associated protein expression predicts good survival in acute myeloid leukemia with normal cytogenetics.Cancer biomarkers : section A of Disease markers · 2023Article
- MiR-20b Tissue Expression Level Displays the Diagnostic Value in Papillary Thyroid Carcinoma.Medical journal of the Islamic Republic of Iran · 2023Article
- Network analysis of synovial RNA sequencing identifies gene-gene interactions predictive of response in rheumatoid arthritis.Arthritis research & therapy · 2022Article
- A Novel Scoring System for Risk Assessment of Elderly Patients With Cytogenetically Normal Acute Myeloid Leukemia Based on Expression of Three AQP1 DNA Methylation-Associated Genes.Frontiers in oncology · 2020Article
- High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.Journal of translational medicine · 2019Article
- Novel biomarkers distinguishing pancreatic head Cancer from distal cholangiocarcinoma based on proteomic analysis.BMC cancer · 2019Article
- Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Article
- Personalizing Chinese medicine by integrating molecular features of diseases and herb ingredient information: application to acute myeloid leukemia.Oncotarget · 2017Article
- MicroRNAs and regulated interaction networks reveal differences between adult and pediatric acute myeloid leukemia.International journal of clinical and experimental pathology · 2017Article
- High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.EBioMedicine · 2016Article
- High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia.Scientific reports · 2016Article
- CircRNAs as New Therapeutic Entities and Tools for Target Identification in Acute Myeloid Leukemia.Cancer genomics & proteomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ATP1B1 encodes the Na,K-ATPase β subunit, a key regulator of the Na+ and K+ electrochemical gradients across the plasma membrane and an essential regulator of cellular activity. We used several microarray datasets to test the prognostic efficacy of ATP1B1 expression in cytogenetically normal acute myeloid leukemia (CN-AML). Within the primary cohort (n = 157), high ATP1B1 expression (ATP1B1(high)) was associated with shorter overall survival (OS) and event-free survival (EFS) (P = 0.0068, P = 0.0039, respectively). Similar results were also obtained in the European Leukemia Net (ELN) Intermediate-I genetic category (OS: P = 0.0035, EFS: P = 0.0007). Multivariable analyses confirmed ATP1B1(high) is an independent predictor of shorter OS (P = 0.042) and EFS (P = 0.035). Analysis of another CN-AML cohort confirmed that ATP1B1(high) is associated with shorter OS (P = 0.0046, n = 162). In addition, up-regulation of oncogenes/onco-microRNAs such as MYCN, CCND2, CDK6, KIT and miR-155, among others, was associated with ATP1B1(high), which may be indicative of ATP1B1's leukemogenicity. Our results may improve risk stratification and indicate new therapeutic targets for CN-AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.